Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 26;2(2):100051.
doi: 10.1016/j.aopr.2022.100051. eCollection 2022 Aug-Sep.

A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema

Affiliations

A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema

Zhiqing Chen et al. Adv Ophthalmol Pract Res. .

Abstract

Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME).

Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26-68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 ​h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P ​< ​0.05 was considered statistically significant.

Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ​± ​12.47 and 79.50 ​± ​10.85, maximal retinal thickness in macular area was 390.95 ​± ​77.12 ​μm and 354.13 ​± ​55.03 ​μm, average retinal thickness in macular area was 334.25 ​± ​36.45 ​μm and 314.31 ​± ​33.28 ​μm, foveal thickness was 287.00 ​± ​46.79 ​μm and 265.63 ​± ​67.14 ​μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P ​< ​0.05). All follow-up results of foveal thickness were not significantly different (P ​> ​0.05) from the baseline result, except that in the 6th month (P ​= ​0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images.

Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation.

Keywords: Dark adaptation; Diabetic macular edema; Diabetic retinopathy; Photobiomodulation; Rod cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
A 33 year old male with type 2 diabetes. A. early retinal FFA telangiectasia before PBM treatment. B. late-stage macular area fluorescence accumulation. C. early retinal FFA telangiectasia relieved significantly after PBM treatment of 12 months. D. Relief in late-stage macular area fluorescence accumulation. E. macular area ETDRS retinal thickness topography before PBM treatment. F. retinal thickness after one-month treatment. G. retinal thickness after two-month treatment. H. retinal thickness after four-month treatment. I. retinal thickness after six-month treatment. J. retinal thickness after 12-month treatment which is significantly lower than the baseline result.

References

    1. Ting D.S.W., Cheung G.C.M., Wong T.Y. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44(4):260–277. doi: 10.1111/ceo.12696. [published Online First: Epub Date] - DOI - PubMed
    1. Mello Filho P., Andrade G., Maia A., et al. Effectiveness and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: A real-world experience. Ophthalmologica. 2019;241(1):9–16. doi: 10.1159/000492132. [published Online First: Epub Date]|. - DOI - PubMed
    1. Iglicki M., Busch C., Zur D., et al. Dexamethasone implant for diabetic macular edema IN naive compared with refractory eyes: The international retina group real-life 24-month multicenter study. The IRGREL-DEX study. Retina. 2019;39(1) - PubMed
    1. Iglicki M., Loewenstein A., Barak A., et al. Outer retinal hyperreflective deposits (ORYD): a new OCT feature in naïve diabetic macular oedema after PPV with ILM peeling. Br J Ophthalmol. 2020;104(5):666. doi: 10.1136/bjophthalmol-2019-314523. [published Online First: Epub Date] - DOI - PubMed
    1. Zur D., Iglicki M., Loewenstein A. The role of steroids in the management of diabetic macular edema. Ophthalmic Res. 2019;62(4):231–236. doi: 10.1159/000499540. [published Online First: Epub Date]|. - DOI - PubMed